垂体腺瘤免疫微环境及免疫治疗的研究进展

Immune microenvironment and immunotherapy of pituitary adenomas

垂体腺瘤(PAs)是第二常见的原发性中枢神经系统肿瘤,多数可通过手术、药物或放射治疗治愈。但是,部分PAs经过传统治疗后仍反复复发并侵袭性生长,甚至发生远端转移,缩短了患者生存期并降低了生活质量。近年来,关于脑肿瘤免疫微环境的研究逐渐兴起,尤其在胶质瘤领域,为免疫治疗提供了潜在有效靶点,为提高患者生存创造了条件。但是,既往研究仅对PAs微环境中免疫细胞、免疫分子及细胞因子进行了初步分析,对动物和人PAs的免疫治疗研究刚刚起步。

Pituitary adenomas(PAs)are the second most common primary central nervous system tumors.Although most PAs can be cured by surgical operation,medicine treatment or radiotherapy,some PAs may recur,invade adjacent structures or even metastasize to other organs after traditional treatments,so decreaseing patient overall survival and deteriorate their life quality.In recent years,studies on the immune microenvironment of brain tumors emerged,especially in the field of glioma,providing potential effective treatment targets for immunotherapy and setting the foundation for improving patient survival.However,previous studies have only conducted preliminary analyses on immune cells,immune molecules,and cytokines in the microenvironment of PAs.The research on immunotherapy of PAs with animal model and humans is only at an early phase.